Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Ontology Browser

Term:
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor (CHEBI:147285)
Annotations: Rat: (5) Mouse: (5) Human: (5) Chinchilla: (0) Bonobo: (0) Dog: (0) Squirrel: (0) Pig: (0)
Parent Terms Term With Siblings Child Terms
calpain inhibitor +   
cathepsin L (EC 3.4.22.15) inhibitor +  
cysteine protease inhibitor +   
EC 3.4.22.2 (papain) inhibitor +  
EC 3.4.22.36 (caspase-1) inhibitor +  
EC 3.4.22.38 (cathepsin K) inhibitor +  
EC 3.4.22.56 (caspase-3) inhibitor +  
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor +   
An EC 3.4.22.* (cysteine endopeptidase) inhibitor that interferes with the action of SARS coronavirus main proteinase (EC 3.4.22.69).

Synonyms
Related Synonyms: 3C-like protease inhibitor ;   3C-like protease inhibitors ;   3cLpro inhibitor ;   3cLpro inhibitors ;   EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitors ;   EC 3.4.22.69 inhibitor ;   EC 3.4.22.69 inhibitors ;   Mpro inhibitor ;   Mpro inhibitors ;   SARS 3C-like protease inhibitor ;   SARS 3C-like protease inhibitors ;   SARS coronavirus 3CL protease inhibitor ;   SARS coronavirus 3CL protease inhibitors ;   SARS coronavirus main peptidase inhibitor ;   SARS coronavirus main peptidase inhibitors ;   SARS coronavirus main protease inhibitor ;   SARS coronavirus main protease inhibitors ;   SARS coronavirus main proteinase inhibitor ;   SARS coronavirus main proteinase inhibitors ;   SARS-CoV 3CLpro enzyme inhibitor ;   SARS-CoV 3CLpro enzyme inhibitors ;   SARS-CoV Mpro inhibitor ;   SARS-CoV Mpro inhibitors ;   SARS-CoV main protease inhibitor ;   SARS-CoV main protease inhibitors ;   coronavirus 3C-like protease inhibitor ;   coronavirus 3C-like protease inhibitors ;   severe acute respiratory syndrome coronavirus main protease inhibitor ;   severe acute respiratory syndrome coronavirus main protease inhibitors
Xrefs: Wikipedia:C30_Endopeptidase

paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.